Godard PP

Jun 20, 2024 | erj.ersjournals.com | O'Byrne PM |Godard PP |P. Jane McDowell |Ron McDowell

To the Editor:We read with interest the editorial “Clinical remission with biologic therapies in severe asthma: a matter of definition” [1]. We absolutely agree that the definition of clinical remission is of critical importance, and as with rheumatology, gastroenterology and dermatology, this is likely to be an iterative process.

Mar 1, 2024 | openres.ersjournals.com | Catherine A. Byrnes |O'Byrne PM |Godard PP |Mark C. Holliday

MethodsThe STep-wise Anti-inflammatory Reliever Therapy Children's Asthma Research (START CARE) study is an investigator-initiated, 52-week, multicentre, open-label, parallel group, phase III, two-sided superiority randomised controlled trial (RCT) based in New Zealand (figure 1). The Medical Research Institute of New Zealand (MRINZ) is the sponsor of the study, which is conducted with support from AstraZeneca Ltd., by both supply of randomised medications and funding of the study.